These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 9139077

  • 1. Use of polymerase chain reaction to provide prognostic information on human cytomegalovirus disease after liver transplantation.
    Lao WC, Lee D, Burroughs AK, Lanzani G, Rolles K, Emery VC, Griffiths PD.
    J Med Virol; 1997 Mar; 51(3):152-8. PubMed ID: 9139077
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G, Einsele H.
    Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Human cytomegalovirus: detection of congenital and perinatal infection in Argentina.
    Distéfano AL, Alonso A, Martin F, Pardon F.
    BMC Pediatr; 2004 Jun 23; 4():11. PubMed ID: 15214967
    [Abstract] [Full Text] [Related]

  • 6. Impact of human cytomegalovirus infection UL55-nested polymerase chain reaction method in hematopoietic stem cell transplant donors and recipients.
    Banan AA, Yaghobi R, Ramzi M, Mehrabani D.
    Transplant Proc; 2009 Sep 23; 41(7):2898-9. PubMed ID: 19765467
    [Abstract] [Full Text] [Related]

  • 7. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS, Preiser W, Kottaridis PD, McKeag N, Brink NS, Tedder RS, Goldstone AH, Linch DC, Mackinnon S.
    Br J Haematol; 2000 Dec 23; 111(3):782-90. PubMed ID: 11122138
    [Abstract] [Full Text] [Related]

  • 8. Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation.
    Emery VC, Cope AV, Sabin CA, Burroughs AK, Rolles K, Lazzarotto T, Landini MP, Brojanac S, Wise J, Maine GT.
    J Infect Dis; 2000 Dec 23; 182(6):1610-5. PubMed ID: 11069231
    [Abstract] [Full Text] [Related]

  • 9. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.
    Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC.
    Transplantation; 2003 Jun 27; 75(12):2064-8. PubMed ID: 12829913
    [Abstract] [Full Text] [Related]

  • 10. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
    Pillet A, Mengelle C, Basse G, Ribes D, Kamar N, Muscari F, Lavayssière L, Suc B, Esposito L, Peron JM, Rostaing L.
    Transplant Proc; 2006 Sep 27; 38(7):2335-8. PubMed ID: 16980083
    [Abstract] [Full Text] [Related]

  • 11. [Direct detection of human cytomegalovirus in urine specimens from bone marrow transplant patients by polymerase chain reaction].
    Ohshima T, Miyachi H, Fusegawa H, Tanaka S, Yabe H, Yabe M, Kato S, Ando Y.
    Rinsho Byori; 1996 Mar 27; 44(3):267-73. PubMed ID: 8857170
    [Abstract] [Full Text] [Related]

  • 12. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
    Madan RP, Campbell AL, Shust GF, Kahn AR, Wistinghausen B, Posada R, Kerkar N, Shneider BL, Emre S, Herold BC.
    Transplantation; 2009 May 15; 87(9):1318-24. PubMed ID: 19424031
    [Abstract] [Full Text] [Related]

  • 13. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF.
    Haematologica; 1999 Jan 15; 84(1):71-9. PubMed ID: 10091394
    [Abstract] [Full Text] [Related]

  • 14. Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation.
    Kim CK, Song JH, Kim SM, Peck KR, Oh W, Huh W, Kim YG, Kim SJ, Joh JW, Lee NY, Park CG, Hwang ES, Cha CY, Oh HY.
    Transplantation; 2003 Jun 27; 75(12):2151-5. PubMed ID: 12829929
    [Abstract] [Full Text] [Related]

  • 15. Follow-up of 28 HCMV seropositive renal-transplant recipients: comparison of clinical, biological and virological parameters in the groups of treated versus untreated infected patients.
    Kamar N, Mengelle C, Yahyaoui S, Sandres-Sauné K, Durand D, Izopet J, Rostaing L.
    J Clin Virol; 2005 May 27; 33(1):35-42. PubMed ID: 15797363
    [Abstract] [Full Text] [Related]

  • 16. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G.
    J Med Virol; 2004 Jul 27; 73(3):412-8. PubMed ID: 15170637
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Lengerke C, Ljubicic T, Meisner C, Loeffler J, Sinzger C, Einsele H, Hebart H.
    Bone Marrow Transplant; 2006 Jul 27; 38(1):53-60. PubMed ID: 16788683
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal monitoring of latent and active human cytomegalovirus infections in peripheral blood of heart transplant recipients by single-tube nested RT-PCR.
    Wolff D, Skourtopoulos M, Hörnschemeyer D, Wolff C, Körner M, Körfer R, Kleesiek K.
    Microbiol Res; 1996 Dec 27; 151(4):343-9. PubMed ID: 9022299
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
    Emery VC, Sabin C, Feinberg JE, Grywacz M, Knight S, Griffiths PD.
    J Infect Dis; 1999 Sep 27; 180(3):695-701. PubMed ID: 10438356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.